Adverum Biotechnologies, Inc. (ADVM) SEC Filing 8-K Material Event for the period ending Thursday, October 18, 2018

Adverum Biotechnologies, Inc.

CIK: 1501756 Ticker: ADVM

View differences made from one to another to evaluate Adverum Biotechnologies, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adverum Biotechnologies, Inc..


Assess how Adverum Biotechnologies, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adverum Biotechnologies, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: ADVM
CIK: 1501756
Form Type: 8-K Corporate News
Accession Number: 0001193125-18-306392
Submitted to the SEC: Wed Oct 24 2018 4:16:01 PM EST
Accepted by the SEC: Wed Oct 24 2018
Period: Thursday, October 18, 2018
Industry: Biological Products No Disgnostic Substances
  1. Event for Officers

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: